Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes.

In the present study, we investigated the therapeutic potential of a selective S1P1 receptor modulator, ponesimod, to protect and reverse autoimmune diabetes in non-obese diabetic (NOD) mice. Ponesimod was administered orally to NOD mice starting at 6, 10, 13 and 16 weeks of age up to 35 weeks of ag...

Full description

Bibliographic Details
Main Authors: Sylvaine You, Luca Piali, Chantal Kuhn, Beat Steiner, Virginia Sauvaget, Fabrice Valette, Martine Clozel, Jean-François Bach, Lucienne Chatenoud
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3811978?pdf=render